胃癌HER2异质性的研究进展
| 作者: |
1卫拴昱,
2肖虹,
2郑绘霞
1 山西医科大学第一临床医学院，太原 030001 2 山西医科大学第一医院病理科，太原 030001 |
| 通讯: |
肖虹
Email: xiaohh9999@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.09.026 |
摘要
胃癌的发病率和病死率较高，目前治疗多以外科手术辅助化疗为主。近年来，以人类表皮生长因子受体2(human epidermal growth factor receptor-2，HER2)为靶点的靶向治疗改善了胃癌患者的生存期，但由于胃癌HER2存在较大的异质性，使得HER2的测定产生一定的假阴性，因此可能使部分能够从中获益的胃癌患者失去靶向治疗的机会。
关键词：
胃癌；人类表皮生长因子受体2；异质性；预后
Research progress of HER2 heterogeneity in gastric cancer
CorrespondingAuthor: XIAO Hong Email: xiaohh9999@163.com
DOI: 10.3978/j.issn.2095-6959.2019.09.026
Abstract
The morbidity and mortality of gastric cancer are high. At present, the majority of treatments are mainly surgical adjuvant chemotherapy. In recent years, targeted therapy targeting human epidermal growth factor receptor 2 (HER2) has improved the survival of patients with gastric cancer, but due to the heterogeneity of HER2 in gastric cancer, the HER2 result assay produces a certain false negative, which may result in some of the gastric cancer patients who are able to benefit from it losing the opportunity for targeted therapy.
Keywords：
gastric cancer; human epidermal growth factor receptor 2 ; heterogeneity; prognosis